Scientists at Stanford have identified a compound that kills most kidney cancer cells without disturbing normal tissue. A new weapon against renal cell carcinoma would be welcome enough. But this research and other recent findings are pointing to how the emerging understanding of autophagy, a natural regulatory process in cells, may be useful in the design of new therapies in cancer and also, potentially, neurodegenerative and immunologic diseases.
Mark L. Ratner
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.
Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.
